Microenvironment mediated alterations to metabolic pathways confer increased chemo-resistance in CD133+ tumor initiating cells

Alice Nomura, Patricia Dauer, Vineet Gupta, Olivia McGinn, Nivedita Arora, Kaustav Majumdar, Charles Uhlrich, Joe Dalluge, Vikas Dudeja, Ashok K Saluja, Sulagna Banerjee

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Chemoresistance in pancreatic cancer has been attributed to tumor-initiating cells (TICs), a minor sub-population of tumor cells. However, the mechanism of chemo-resistance in these cells is still unclear. In the current study, immunohistochemical analysis of LSL-KrasG12D; LSL-Trp53R172H; PdxCre (KPC) murine tumors indicated that hypoxic regions developed through tumor progression. This hypoxic "niche" correlated with increased CD133+ population that had an increased HIF1A activity. Consistent with this observation, CD133+ cells had increased glucose uptake and activity of glycolytic pathway enzymes compared to CD133- cells. Mass spectrometric analysis (UPLC-TQD) following metabolic labeling of CD133+ cells with [13C]-U6 glucose confirmed this observation. Furthermore, although both populations had functionally active mitochondria, CD133+ cells had low mitochondrial complex I and complex IV activity and lesser accumulation of ROS in response to standard chemotherapeutic compounds like paclitaxel, 5FU and gemcitabine. CD133+ cells also showed increased resistance to all three chemotherapeutic compounds and treatment with Glut1 inhibitor (STF31) reversed this resistance, promoting apoptotic death in these cells similar to CD133- cells. Our study indicates that the altered metabolic profile of CD133+ pancreatic TIC protects them against apoptosis, by reducing accumulation of ROS induced by standard chemotherapeutic agents, thereby confering chemoresistance. Since resistance to existing chemotherapy contributes to the poor prognosis in pancreatic cancer, our study paves the way for identifying novel therapeutic targets for managing chemoresistance and tumor recurrence in pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)56324-56337
Number of pages14
JournalOncotarget
Volume7
Issue number35
DOIs
StatePublished - Jan 1 2016

Fingerprint

Neoplastic Stem Cells
Metabolic Networks and Pathways
Pancreatic Neoplasms
gemcitabine
Neoplasms
Population
Glucose
Metabolome
Paclitaxel
Fluorouracil
Mitochondria
Cell Death
Apoptosis
Recurrence
Drug Therapy
Enzymes
Therapeutics

Keywords

  • CD133
  • Hypoxia
  • Metabolism
  • ROS
  • Tumor initiating cells

Cite this

Microenvironment mediated alterations to metabolic pathways confer increased chemo-resistance in CD133+ tumor initiating cells. / Nomura, Alice; Dauer, Patricia; Gupta, Vineet; McGinn, Olivia; Arora, Nivedita; Majumdar, Kaustav; Uhlrich, Charles; Dalluge, Joe; Dudeja, Vikas; Saluja, Ashok K; Banerjee, Sulagna.

In: Oncotarget, Vol. 7, No. 35, 01.01.2016, p. 56324-56337.

Research output: Contribution to journalArticle

Nomura, Alice ; Dauer, Patricia ; Gupta, Vineet ; McGinn, Olivia ; Arora, Nivedita ; Majumdar, Kaustav ; Uhlrich, Charles ; Dalluge, Joe ; Dudeja, Vikas ; Saluja, Ashok K ; Banerjee, Sulagna. / Microenvironment mediated alterations to metabolic pathways confer increased chemo-resistance in CD133+ tumor initiating cells. In: Oncotarget. 2016 ; Vol. 7, No. 35. pp. 56324-56337.
@article{e0dc0950967041e282115e9d70efb6d3,
title = "Microenvironment mediated alterations to metabolic pathways confer increased chemo-resistance in CD133+ tumor initiating cells",
abstract = "Chemoresistance in pancreatic cancer has been attributed to tumor-initiating cells (TICs), a minor sub-population of tumor cells. However, the mechanism of chemo-resistance in these cells is still unclear. In the current study, immunohistochemical analysis of LSL-KrasG12D; LSL-Trp53R172H; PdxCre (KPC) murine tumors indicated that hypoxic regions developed through tumor progression. This hypoxic {"}niche{"} correlated with increased CD133+ population that had an increased HIF1A activity. Consistent with this observation, CD133+ cells had increased glucose uptake and activity of glycolytic pathway enzymes compared to CD133- cells. Mass spectrometric analysis (UPLC-TQD) following metabolic labeling of CD133+ cells with [13C]-U6 glucose confirmed this observation. Furthermore, although both populations had functionally active mitochondria, CD133+ cells had low mitochondrial complex I and complex IV activity and lesser accumulation of ROS in response to standard chemotherapeutic compounds like paclitaxel, 5FU and gemcitabine. CD133+ cells also showed increased resistance to all three chemotherapeutic compounds and treatment with Glut1 inhibitor (STF31) reversed this resistance, promoting apoptotic death in these cells similar to CD133- cells. Our study indicates that the altered metabolic profile of CD133+ pancreatic TIC protects them against apoptosis, by reducing accumulation of ROS induced by standard chemotherapeutic agents, thereby confering chemoresistance. Since resistance to existing chemotherapy contributes to the poor prognosis in pancreatic cancer, our study paves the way for identifying novel therapeutic targets for managing chemoresistance and tumor recurrence in pancreatic cancer.",
keywords = "CD133, Hypoxia, Metabolism, ROS, Tumor initiating cells",
author = "Alice Nomura and Patricia Dauer and Vineet Gupta and Olivia McGinn and Nivedita Arora and Kaustav Majumdar and Charles Uhlrich and Joe Dalluge and Vikas Dudeja and Saluja, {Ashok K} and Sulagna Banerjee",
year = "2016",
month = "1",
day = "1",
doi = "10.18632/oncotarget.10838",
language = "English (US)",
volume = "7",
pages = "56324--56337",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "35",

}

TY - JOUR

T1 - Microenvironment mediated alterations to metabolic pathways confer increased chemo-resistance in CD133+ tumor initiating cells

AU - Nomura, Alice

AU - Dauer, Patricia

AU - Gupta, Vineet

AU - McGinn, Olivia

AU - Arora, Nivedita

AU - Majumdar, Kaustav

AU - Uhlrich, Charles

AU - Dalluge, Joe

AU - Dudeja, Vikas

AU - Saluja, Ashok K

AU - Banerjee, Sulagna

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Chemoresistance in pancreatic cancer has been attributed to tumor-initiating cells (TICs), a minor sub-population of tumor cells. However, the mechanism of chemo-resistance in these cells is still unclear. In the current study, immunohistochemical analysis of LSL-KrasG12D; LSL-Trp53R172H; PdxCre (KPC) murine tumors indicated that hypoxic regions developed through tumor progression. This hypoxic "niche" correlated with increased CD133+ population that had an increased HIF1A activity. Consistent with this observation, CD133+ cells had increased glucose uptake and activity of glycolytic pathway enzymes compared to CD133- cells. Mass spectrometric analysis (UPLC-TQD) following metabolic labeling of CD133+ cells with [13C]-U6 glucose confirmed this observation. Furthermore, although both populations had functionally active mitochondria, CD133+ cells had low mitochondrial complex I and complex IV activity and lesser accumulation of ROS in response to standard chemotherapeutic compounds like paclitaxel, 5FU and gemcitabine. CD133+ cells also showed increased resistance to all three chemotherapeutic compounds and treatment with Glut1 inhibitor (STF31) reversed this resistance, promoting apoptotic death in these cells similar to CD133- cells. Our study indicates that the altered metabolic profile of CD133+ pancreatic TIC protects them against apoptosis, by reducing accumulation of ROS induced by standard chemotherapeutic agents, thereby confering chemoresistance. Since resistance to existing chemotherapy contributes to the poor prognosis in pancreatic cancer, our study paves the way for identifying novel therapeutic targets for managing chemoresistance and tumor recurrence in pancreatic cancer.

AB - Chemoresistance in pancreatic cancer has been attributed to tumor-initiating cells (TICs), a minor sub-population of tumor cells. However, the mechanism of chemo-resistance in these cells is still unclear. In the current study, immunohistochemical analysis of LSL-KrasG12D; LSL-Trp53R172H; PdxCre (KPC) murine tumors indicated that hypoxic regions developed through tumor progression. This hypoxic "niche" correlated with increased CD133+ population that had an increased HIF1A activity. Consistent with this observation, CD133+ cells had increased glucose uptake and activity of glycolytic pathway enzymes compared to CD133- cells. Mass spectrometric analysis (UPLC-TQD) following metabolic labeling of CD133+ cells with [13C]-U6 glucose confirmed this observation. Furthermore, although both populations had functionally active mitochondria, CD133+ cells had low mitochondrial complex I and complex IV activity and lesser accumulation of ROS in response to standard chemotherapeutic compounds like paclitaxel, 5FU and gemcitabine. CD133+ cells also showed increased resistance to all three chemotherapeutic compounds and treatment with Glut1 inhibitor (STF31) reversed this resistance, promoting apoptotic death in these cells similar to CD133- cells. Our study indicates that the altered metabolic profile of CD133+ pancreatic TIC protects them against apoptosis, by reducing accumulation of ROS induced by standard chemotherapeutic agents, thereby confering chemoresistance. Since resistance to existing chemotherapy contributes to the poor prognosis in pancreatic cancer, our study paves the way for identifying novel therapeutic targets for managing chemoresistance and tumor recurrence in pancreatic cancer.

KW - CD133

KW - Hypoxia

KW - Metabolism

KW - ROS

KW - Tumor initiating cells

UR - http://www.scopus.com/inward/record.url?scp=84984904226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984904226&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.10838

DO - 10.18632/oncotarget.10838

M3 - Article

C2 - 27472388

AN - SCOPUS:84984904226

VL - 7

SP - 56324

EP - 56337

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 35

ER -